Short Interest in 20/20 Biolabs Inc (NASDAQ:AIDX) Increases By 613.4%

20/20 Biolabs Inc (NASDAQ:AIDX) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 128,775 shares, an increase of 613.4% from the May 14th total of 18,050 shares. Based on an average daily volume of 1,125,074 shares, the short-interest ratio is presently 0.1 days. Currently, 1.2% of the shares of the company are sold short.

20/20 Biolabs Price Performance

Shares of 20/20 Biolabs stock traded up $0.02 during trading hours on Friday, reaching $0.88. The company had a trading volume of 26,500 shares, compared to its average volume of 327,998. 20/20 Biolabs has a one year low of $0.78 and a one year high of $50.00. The business has a fifty day moving average price of $1.40.

20/20 Biolabs (NASDAQ:AIDX) last posted its quarterly earnings results on Wednesday, May 20th. The company reported ($0.28) EPS for the quarter. The firm had revenue of $0.35 million during the quarter.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on AIDX. Wall Street Zen raised 20/20 Biolabs to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings began coverage on 20/20 Biolabs in a report on Thursday, May 14th. They set a “sell (e-)” rating for the company. Finally, Maxim Group began coverage on 20/20 Biolabs in a report on Monday, May 11th. They set a “buy” rating and a $5.00 price objective for the company. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, 20/20 Biolabs has a consensus rating of “Hold” and a consensus price target of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.